Nivolumab-ipilimumab and Chemoradiation for Cervical Cancer

This study is testing a combination of two immunotherapy drugs — nivolumab and ipilimumab — added to standard chemoradiation (chemotherapy plus radiation) for women with locally advanced cervical cancer. Immunotherapy helps the immune system attack cancer cells. Researchers want to see if adding it to the standard treatment improves outcomes. **You may be eligible if...** - You are a woman over 18 with cervical cancer (adenocarcinoma or squamous carcinoma) - Your cancer is locally advanced (FIGO stage IB2–IB3 with lymph node spread, or stages IIB–IVA) - You have not received prior chemotherapy, immunotherapy, or radiation for cervical cancer - You are in good general health (ECOG 0–1) **You may NOT be eligible if...** - You have a rare small cell or neuroendocrine type of cervical cancer - You have already had a hysterectomy - You have distant metastases - You have active autoimmune disease or a history of organ transplant - You are pregnant or planning a fertility-sparing approach - You have had another primary cancer Talk to your doctor to see if this trial is right for you.